Inobrodib, a potent and selective p300/CBP bromodomain inhibitor, is targeted and differentiated from BET inhibitors in prostate cancer cell lines in vitro.

p300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumour AR and c-Myc gene expression in vivo.

A first-in-class p300/CBP bromodomain inhibitor for the treatment of prostate cancer and hematologic malignancies.

Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond

Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer (CRPC)

Targeting the bromodomain of p300/CBP for the treatment of castrate resistant prostate cancer

Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of CRPC

Novel small molecule inhibitors of p300/CBP down-regulate AR and c-Myc for the treatment of CRPC

A novel small molecule inhibitor of p300/CBP for the treatment of CRPC – preclinical evaluation